Aclidinium Bromide Gains Reluctant Advisory Committee Recommendation
This article was originally published in The Pink Sheet Daily
Executive Summary
Pulmonary-Allergy Drugs Advisory Committee members say post-marketing study is necessary, and Forest has already made a preliminary proposal.